Tag
NYSE: BMY
- Neurocrine Biosciences starts 135‑patient Alzheimer's cognition trial
- Liquidia Corporation agrees to US$380.7M litigation settlement
- Johnson & Johnson raises 2026 outlook after US$25.4B quarterly sales
- Syndax Pharmaceuticals ends IPF development after Phase 2 axatilimab miss
- Bristol Myers Squibb reports admilparant trial success as higher dose misses
- Bristol Myers Squibb reports 51% lower progression or death risk with Zenbexus regimen
- Takeda details 36.5% complete clearance versus Sotyktu in Phase 3
- Merck closes SciBrunch KRAS licence worth up to US$2.13B
- Lung cancer innovations showcased at ASCO 2026 as researchers pursue earlier detection
- Novartis advances actinium-based cancer drug after promising trial data
- Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug
- Puma Biotechnology shares get favourable price bump on strong Q2 results
- Checkpoint Therapeutics gets picked up by Sun Pharma, enjoys 60% share bump
- Edgewise Therapetics shares skyrocket on positive clinical trial returns
- New drug could open personalized treatment strategies for prostate cancer